Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

被引:52
|
作者
Reece, E. Albert [1 ]
机构
[1] Univ Maryland, Sch Med, Baltimore, MD 21210 USA
关键词
Antioxidant therapy; Birth defects; Fatty acid; Folic acid; Diabetic embryopathy; Dietary supplementation; Hyperglycemia; Infant mortality; Pregnancy; Glucose control; Molecular pathogenesis; Preconception care; Diabetes; INOSITOL POLYPHOSPHATES; CONGENITAL-ANOMALIES; SUPEROXIDE-DISMUTASE; INSULIN THERAPY; UNITED-STATES; EMBRYOPATHY; PREGNANCY; HYPERGLYCEMIA; PREVENTION; ACTIVATION;
D O I
10.1007/s11892-011-0251-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Birth defects are the leading cause of infant mortality in the United States, which has one of the highest infant mortality rates in the developed world. Many of these birth defects can be attributed to pre-existing, or pregestational, diabetes in pregnancy, which significantly increases a mother's risk of having a child with a major birth defect. Strict preconceptional and early pregnancy glucose control, supplementation with multivitamins and fatty acids, and lower glycemic dietary management have been shown to reduce the incidence of birth defects in experimental and epidemiologic studies. However, because more than half of pregnancies are unplanned, these methods are not generalizable across the population. Thus, better interventions are urgently needed. Based on what we know about the molecular pathophysiology of diabetic embryopathy, our laboratory and others are developing interventions against to key molecular targets in this multifactorial disease process.
引用
收藏
页码:24 / 32
页数:9
相关论文
共 50 条
  • [31] Sex Differences in Heart Failure: What Do We Know?
    Arata, Allegra
    Ricci, Fabrizio
    Khanji, Mohammed Y.
    Mantini, Cesare
    Angeli, Francesco
    Aquilani, Roberta
    Di Baldassarre, Angela
    Renda, Giulia
    Mattioli, Anna Vittoria
    Nodari, Savina
    Gallina, Sabina
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (07)
  • [32] Maternal Transport, What Do We Know: A Narrative Review
    Barnes, Sally G.
    Sutliff, Bailey
    Wendel, Michael P.
    Magann, Everett F.
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2024, 16 : 877 - 889
  • [33] Chloroquine and hydroxychloroquine during pregnancy: What do we know?
    Lacroix, Isabelle
    Benevent, Justine
    Damase-Michel, Christine
    THERAPIE, 2020, 75 (04): : 384 - 385
  • [34] Pulmonary arterial hypertension in SLE: what do we know?
    Prabu, A.
    Gordon, C.
    LUPUS, 2013, 22 (12) : 1274 - 1285
  • [35] Electronic Cigarettes and Pregnancy - What Do We Currently Know?
    Nieslony, Filip
    Nieslony, Dominik
    Mado, Hubert
    ELECTRONIC JOURNAL OF GENERAL MEDICINE, 2022, 19 (01):
  • [36] What do we know about the inflammasome in humans?
    Amin, Jay
    Boche, Delphine
    Rakic, Sonja
    BRAIN PATHOLOGY, 2017, 27 (02) : 192 - 204
  • [37] Napping and Obesity in Adults - What do we Know?
    Wannamethee, Sasiwarang Goya
    CURRENT DIABETES REPORTS, 2024, 24 (11) : 237 - 243
  • [38] Anthocyanins: What do we know until now?
    Giampieri, Francesca
    Cianciosi, Danila
    Alvarez-Suarez, Jose M.
    Quiles, Jose L.
    Forbes-Hernandez, Tamara Y.
    Navarro-Hortal, Maria D.
    Machi, Michele
    Pali Casanova, Ramon del Jesus
    Martinez Espinosa, Julio Cesar
    Chen, Xiumin
    Di Zhang
    Bai, Weibin
    Tian Lingmin
    Mezzetti, Bruno
    Battino, Maurizio
    Diaz, Yasmany Armas
    JOURNAL OF BERRY RESEARCH, 2023, 13 (01) : 1 - 6
  • [39] Coxiella burnetii Lipopolysaccharide: What Do We Know?
    Abnave, Prasad
    Muracciole, Xavier
    Ghigo, Eric
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (12)
  • [40] Safety of bronchodilators and corticosteroids for asthma during pregnancy: what we know and what we need to do better
    Gregersen, Thorbjorn Lomholt
    Ulrik, Charlotte Suppli
    JOURNAL OF ASTHMA AND ALLERGY, 2013, 6 : 117 - 125